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Abstract
After surgical intervention with curative intention in specialised centres the five-year survival of patients with
carcinoma of the exocrine pancreas is only 15%. The ESPAC-1 trial showed an increased five-year survival of 21%
achieved with adjuvant chemotherapy. Investigators from the Virginia Mason Clinic have reported a 5-year
survival rate of 55% in a phase II trial evaluating adjuvant chemotherapy, immunotherapy and external-beam
radiation.
Design: The CapRI study is an open, controlled, prospective, randomised multi-centre phase III trial. Patients in
study arm A will be treated as outpatients with 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b
for 5 1/2 weeks combined with external beam radiation. After chemo-radiation the patients receive continuous
5-FU infusions for two more cycles. Patients in study arm B will be treated as outpatients with intravenous bolus
injections of folinic acid, followed by intravenous bolus injections of 5-FU given on 5 consecutive days every 28
days for 6 cycles. A total of 110 patients with specimen-proven R0 or R1 resected pancreatic adenocarcinoma
will be enrolled. An interim analysis for patient safety reasons will be done one year after start of recruitment.
Evaluation of the primary endpoint will be performed two years after the last patients' enrolment.
Discussion: The aim of this study is to evaluate the overall survival period attained by chemo-radiotherapy
including interferon alpha 2b administration with adjuvant chemotherapy. The influence of interferon alpha on the
effectiveness of the patients' chemoradiation regimen, the toxicity, the disease-free interval and the quality of life
are analysed. Different factors are tested in terms of their potential role as predictive markers.
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Background
Only 10–20% of patients with pancreatic cancer can be
resected with curative intent at the time of diagnosis.
Loco-regional recurrence and/or metastatic disease
develop in the majority of patients who undergo pancre-
atic resection. Relapse occurs within 9–15 months after
initial presentation and patients have median life expect-
ancies of only 12–15 months without adjuvant therapy.
The 5-year survival rate of patients with resected pancre-
atic adenocarinoma is approximately 20% [1]. The statis-
tics for the 80 to 90 % of patients who present with locally
advanced and metastatic pancreatic cancer are even more
dismal. Rarely do such patients achieve a complete
response to treatment; median survival is 5–10 months
and 5-year survival is near zero [2].
There is very little randomised data on adjuvant therapy
for pancreatic carcinoma. The ESPAC-1 trial assessed the
role of adjuvant therapy in a randomized study. 548
patients were enrolled in Europe in this first large rand-
omized trial. There was evidence that adjuvant chemo-
therapy brought survival benefits. The five-year survival
rate was 21 percent among patients who received chemo-
therapy [3].
In 1995 a phase II trial was initiated by the Virginia Mason
Clinic, Seattle, USA combining pancreaticoduodenec-
tomy and adjuvant therapy with 5-FU, cisplatin, inter-
feron alpha and radiation therapy. Picozzi et al. reported
treatment and results in a series of 43 patients with high-
risk resected pancreatic adenocarcinoma (84% node pos-
itive, 19% margin positive). After a median follow-up
period of 32 months the 2-year survival rate was 64% and
the 5-year survival rate was 55% [4]. The overall recur-
rence rate was 12% of which 80% occurred within 2 years
after surgery [5].
Since the Virginia Mason group reported such encourag-
ing results in improving survival periods, there has been
considerable interest in gaining increased experience with
this therapy combination in an effort to confirm results
and evaluate the toxicity profile of a modified version of
this regimen.
Radio-sensitising properties of 5-FU (5-fluorouracil) and
cisplatin are well known. The incorporation of interferon
alpha-2b into a combined modality treatment program
seems to offer a number of theoretical advantages. These
include: 1) the radio-sensitisation effects of interferon
alpha-2b and 5-FU perhaps synergistically [6]; 2)
enhanced 5-FU based bio-availability; 3) a synergistic
inhibition of pyrimidine metabolism with 5-FU; and 4)
an independent immunomodulatory effect of interferon
alpha-2b [7]. 5-FU and interferon alpha-2b have been
used together to advantage in several cancer settings, but
not as part of a combined modality program [8]. Cisplatin
also has a radio-sensitising effect and shares similar prop-
erties of cytotoxic synergy with interferon alpha-2b and 5-
FU in both experimental and clinical cancer systems [9].
In a previous study we were able to demonstrate in vitro
that interferon alpha has direct inhibitory properties and
that it reduces the enhanced proliferation rate and VEGF
secretion after a single treatment with cisplatin [10]. The
use of interferon alpha-2b, 5-FU and cisplatin together
thus might represent a kind of "combination radiosensi-
tizer" analogous to combination chemotherapy poten-
tially useful in the treatment of pancreaticobiliary cancers,
especially from the standpoint of local control.
Design
Trial organization
CapRI has been designed by the Department of Surgery,
University of Heidelberg. The trial is carried out by the
National Centre for Tumourdiseases (NCT). The NCT is a
multidisciplinary clinical and basic research group as well
as comprehensive cancer centre of the Medical School of
the University of Heidelberg that has been founded to
improve care and research for cancer patients. The trial is
sponsored by the Manfred-Lautenschläger-Foundation.
The sponsor is not involved in the database management
and has no access to the randomisation code.
Coordination
The trial is co-ordinated by the Surgical Department in
cooperation with the National Centre for Tumourdiseases
(NCT) at the University of Heidelberg. The Dept. of Sur-
gery is responsible for overall trial management, trial reg-
istration (International Standard Randomised Controlled
Trial Number (ISRCTN 62866759), http://www.control
led-trials.com), database management, quality assurance
including monitoring, reporting and for the scientific pro-
gram of all trial related meetings.
Investigators
Patients will be recruited by the Department of Surgery at
the University of Heidelberg. Due to the multi-modal
nature of the trial, all investigators are experienced oncol-
ogists from the fields of hematology/oncology, radiation
oncology and general surgery at the University of Heidel-
berg co-operating in this trial.
Adverse events committee
This committee consists of 3 independent physicians
(medical oncologist, radiation oncologist and surgeon)
and decides on the final diagnostic classification of critical
clinical events. For all serious adverse events the docu-
mentation and relevant patient data are verified by the co-
ordinating personnel before submitting the data to the
Adverse Events Committee for diagnostic classification.BMC Cancer 2005, 5:37 http://www.biomedcentral.com/1471-2407/5/37
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Analysis of safety related data is performed with respect to
frequency of:
• Serious Adverse Events and Adverse Events stratified by
body-system
• Adverse Events stratified by severity
• Adverse Events stratified by causality.
Patient toxicities will be assessed using the NCI Common
Toxicity Criteria (CTC). Toxicity will be evaluated pre-
treatment, weekly during chemoradiation/ chemother-
apy, prior to each course of infusional 5-FU and at follow-
up. Unacceptable toxicity is defined as unpredictable, or
irreversible Grade 4 toxicity. Decisions regarding weekly
chemoradiation treatment and chemotherapy dose-
adjustment will be made using the guidelines below and
based on hematological parameters (ANC and platelets)
monitored weekly during chemoradiation before each
dose of cisplatin.
Medication supply
All chemotherapeutic and immunotherapeutic agents are
prepared and provided by the pharmacy of the University
Hospital Heidelberg. Medication will be prepared for each
patient specifically and delivered just prior to administra-
tion to the NCT.
On-site monitoring
During recruitment of patients monitoring on site is per-
formed according to good clinical practice (GCP) guide-
lines. The monitoring for this trial will be performed by a
monitor from a Clinical Research Organisation (CRO)
who is not involved in the trial or in completion of the
case report form (CRF). The data management will be per-
formed by an independent medical documentalist from
the Institute for Medical Bioinformatics, University of
Heidelberg. The medical monitoring will be done by two
independent oncologists not involved in conducting this
trial.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Medical School (L-042/
2003). This study complies with the Helsinki Declaration
in its recent German version, the Medical Association's
professional code of conduct, the principles of Good Clin-
ical Practice (GCP) guidelines and the Federal Data Pro-
tection Act. The trial will also be carried out in keeping
with local legal and regulatory requirements. The medical
secrecy and the Federal Data Protection Act will be
followed.
Written informed consent is obtained from each patient
in oral and written form before inclusion in the trial and
the nature, scope, and possible consequences of the trial
have been explained by a physician. The investigator will
not undertake any measures specifically required only for
the clinical trial until valid consent has been obtained.
Patient selection
CapRI focuses on hospitalised patients over 18 years of
age treated with pancreatic head resection for pancreatic
adenocarcinoma during an 18-month period started in
August 2004. Men and women over eighteen years of age
with biopsy-proven completely resected (R0 or R1) pan-
creatic adenocarcinoma of the pancreatic head or unci-
nate process will be screened for participation in the
study. A detailed overview of all eligibility criteria is given
in Table 2.
Study design
The CapRI study is designed as an open, controlled, pro-
spective, randomised potentially multi-centre trial meant
to evaluate the post-operative overall survival of patients
with pancreatic adenocarcinoma receiving chemo-radio-
therapy including interferon alpha 2b administration
compared with adjuvant chemotherapy. The treatment is
offered to a heterogeneous group of people under clinical
circumstances, covering a wide age range, for both sexes
and with heterogeneous characteristics / co-morbidities.
One year after inclusion of the first patient an interim
analysis will be performed. If at this time point there is
already a significant difference between both groups
favouring the Virginia Mason scheme (p < 0.001) group B
(5-FU/Folinic acid) will be stopped and replaced by group
C (chemoradiation without interferon alpha). This group
will help to define the possibly deciding influence of
interferon alpha on the effectiveness of the Virginia
Mason treatment protocol. Addition of group C to the
study would be the matter of a separate study amend-
ment. The study design will not be changed prior to agree-
ment of the ethics committee.
Study objectives
The primary objective is to compare the overall survival at
two years postoperatively between two different methods
of adjuvant treatment: therapy with 5-FU, cisplatin, inter-
feron alpha 2b combined with radiation and the standard
treatment from the ESPAC-1-Trial with 5-FU plus folinic
acid.
Secondary objectives are to determine the role and the
mechanism of interferon alpha 2b in patient's chemoradi-
ation regimen, the toxicity, the disease-free interval and
the quality of life. Different factors are tested in terms of
their potential role as predictive markers.BMC Cancer 2005, 5:37 http://www.biomedcentral.com/1471-2407/5/37
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Randomisation and standardised treatment scheme
A block-randomisation-list is generated via computer sys-
tem (SAS Version 8.2, SAS Institute Inc., Cary, USA). The
sealed randomisation list is stored in the investigator file.
Patients are randomised using sealed opaque envelopes in
the independent study centre at the Department of Sur-
gery (Clinical Study Centre – "Klinisches Studienzentrum
Chirurgie" – KSC) until informed consent is attained and
diagnostic procedures rule out any contra-indication for
participation in this trial.
After randomisation and pre-treatment evaluation treat-
ment must begin within 12 weeks of surgery. A port cath-
eter will be placed after informed consent and
randomisation will be done within one to two weeks after
pancreatoduodenectomy for patients in study arm A.
These patients will be treated with 200 mg/m2/day 5-FU
by continuous intravenous infusion at days 1–38.
Cisplatin – 30 mg/m2 (maximum single cisplatin dose of
60 mg) iv over 60 minutes on days 1, 8, 15, 22, 29, 36 (6
doses). Two to three hours before and after cisplatin
administration the patients will receive hydration of at
least 2 litres.
Interferon alpha-2b (Intron A) will be administered at a
dose of 3 million units subcutaneously three times weekly
(Monday, Wednesday, and Friday) for 17 doses. Non-ster-
oidal anti-inflammatory drugs and steroids should be
avoided if possible during Intron A treatment.
External beam radiation is to be given concurrently with
chemotherapy with a total dose of 50.4 Gy in 28 fractions
over 5.5 weeks (1.8 Gy/day). The pancreatic bed (i. e.
resection margin) will be covered with a minimum mar-
gin of 2 cm. The hepatoduodenal ligament, origins of the
celiac axis and superior mesenteric artery will be included.
The AP/PA fields must include the entire duodenal C-loop
as seen on the pre-operative CT scan. All patients will
receive XRT per informed consent. A four-field technique
with AP/PA and lateral fields and customised blocking is
required. The beams will be weighted more heavily in the
AP/PA fields (usually 2:1 compared to the lateral fields).
The dose contribution from the lateral fields should be
restricted to 20 Gy. Simulation should be done with the
patient in the supine position with "arms up" position. A
dosage greater than or equal to 10 MV photons should be
used.
In study arm A the patients receive post-chemoradiation
5-FU infusions of 200/mg/m2 /day by continuous intrave-
nous infusion on days 64–101 and 120–161. The timing
of these courses of infusional 5-FU will be adjusted in
patients who have treatment interruptions.
Patients in study arm B will be treated with 20 mg/m2
intravenous bolus injection of Folinic acid, D-L form, fol-
lowed by 425 mg/m2/day intravenous bolus injection of
5-FU given on 5 consecutive days every 28 days for 6
cycles, i.e. 24 weeks.
The treatment protocol is outlined in figure 1.
Investigation schedule and follow-up
Pre-treatment evaluation for patients who are enrolled in
study arm A includes a single low-dose (3 Mio U) injec-
tion of INTRON A prior to therapy (LDI). Blood will be
drawn for intensive immunological studies. All patients
CapRI treatment scheme Figure 1
CapRI treatment scheme.BMC Cancer 2005, 5:37 http://www.biomedcentral.com/1471-2407/5/37
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(study arm A or B) must have appropriate lab and
radiographic studies (CXR; CT abdomen [done post-oper-
atively]; CBC; platelet count; BUN; creatinine; bilirubin,
CA 19-9, and CEA) conducted prior to study enrolment to
meet eligibility criteria.
During days 1–38 [study arm A] or during chemotherapy
[study arm B] patients will be assessed with laboratory
evaluation: complete blood count and blood chemistries
weekly. Laboratory parameters in study arm A will be eval-
uated before each dose of cisplatin. Creatinine will be
determined also one day after administration of cisplatin.
Blood from members of study arm A will be investigated
weekly for immunological markers.
Vital signs (blood pressure and pulse rate) and tempera-
ture are controlled daily during treatment. Patients are
evaluated prior to receiving chemoradiation or chemo-
therapy. Patients enrolled in study arm A are evaluated
weekly by the medical oncology and radiation oncology
team during treatment. The team will check patients at
each visit for symptoms due to therapy; a physical exami-
nation and complete safety labs should be performed. The
patients' mental state will be investigated weekly. The
questionnaire CES-D will be used as support. The three
module questionnaire will be filled out during weeks 3
and 6 (study arm A) or week 3 and week 24 for study arm
B.
During post-chemoradiation, infusional 5-FU (Study Arm
A) patients will be evaluated by a physician prior to treat-
ment and every 2 to 3 weeks with clinical assessment and
laboratory parameters including a CBC, electrolytes, BUN,
and creatinine. If patients undergo post chemoradiother-
apy infusional 5-FU coordinated by an outside medical
oncologist, a study nurse will contact the patient at least
once weekly by telephone.
In the post-treatment period patients will be seen every 3
months by the surgical service for the first 2 years, every 4
months for the third year, and every 6 months during the
4th and 5th post-treatment years.
The aggregate clinical, laboratory, and imaging evalua-
tions required per protocol as well as the timing of the
optional three module questionnaire are outlined in table
1.
The follow-up will be continued for two years. Follow-up
data of overall survival will be evaluated annually.
Assessment of quality of life
Measurement of quality of life is one of the secondary
objectives of the trial. Overall survival, return to previous
employment as well as persistence of symptoms, the abil-
ity to perform appropriate activities and to care for oneself
are criteria applied in the three questionnaires used in this
study.
EORTC QLQ-C30 is a general measure of qualitiy of life in
cancer patients. It incorporates nine multi-item scales: five
functional scales (physical, role, cognitive, emotional,
and social); three symptom scales (fatigue, pain, and nau-
sea and vomiting); and a global health and quality-of-life
scale [17]. Specific symptoms (dyspnoea, insomnia, ano-
rexia, constipation, diarrhoea, and financial impact) are
measured as six single items. This instrument has been
used extensively with a variety of cancer patients and was
able to discriminate between individuals with metastatic
and non-metastatic disease, as well as between patients at
different stages of illness. The scale has good internal con-
sistency (alpha > 0.70), and good test re-test reliability
(0.80 to 0.90) [18].
To assess disease-specific symptoms for patients with pan-
creatic cancer the pancreatic specific module (QLQ-
PAN26) [19] that has been designed to use long with the
general measure is used in this study.
The CES-D [20] is a 20-item self-report measure of depres-
sion that emphasises the emotional dimension. Its
emphasis on the affective components of depression and
is preferable for use in medical populations. It has dem-
onstrated high internal consistency in both the general
population and in patient populations and convergent
validity with other measures of depression [21].
Evaluation of the role of interferon alpha
In addition to the Virginia Mason and the MD Anderson
study, an investigation of the effects and mechanism of
INTRON A will be performed. IFN alpha seems to have
the greatest activity of all interferons in malignancies [21-
23] but its mode of action is poorly understood.
It probably consists of a combination of stimulation of
cell-mediated cytotoxicity [24,25], direct antiproliferative
anti-tumour activity, and an anti-angiogenic effect [15,26-
31]. The known molecular and cellular effects of IFN-
alpha appear to complement the mechanism of action of
other therapies [28].
In view of the significant improvement in survival rates
achieved by using interferon alpha in the Virginia Mason
study, studies are now needed to define the molecular and
immunologic mechanism(s) of this modality. If the
mechanism of action of IFN-alpha is more clearly under-
stood it can be applied more selectively and its therapeutic
index will be enhanced.BMC Cancer 2005, 5:37 http://www.biomedcentral.com/1471-2407/5/37
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Patients in study arm A at the CapRI trial will receive a sin-
gle low-dose injection of 1 million units (LDI) prior to
therapy. Accompanying immunological analysis should
help to define predictive response markers. During ther-
apy patients blood samples of approx. 20 ml will be
drawn once a week for immunological studies. The panel
will include immunophenotypings, detection of cytokine
mRNA in lymphocytes, determination of cytokine pat-
terns in peripheral blood, cellular cytotoxicity assays
against autologous tumor cells and determination of
apoptotic effects of interferon against autologous tumor
cells.
Statistical considerations and sample size estimation
The primary endpoint in this study is the overall survival
period, measured from the date of resection. The sample
size calculation is based on the assumption of a constant
monthly hazard rate of 0.044 in the standard group and a
constant monthly hazard rate of 0.021 in the experimen-
tal group. The hazard values are derived from two-year
survival rates in the study groups (using the formula λgroup
= -1 × ln(P24,group)/24) with a two-year survival rate of
35% in the control group [11,12]and a conservative two-
year survival rate of 60% in study arm A[13].
Assuming an accrual period of 18 months and a follow-up
of 42 months [14,15], testing for a difference in hazard
(hazard ratio ≠ 1) on level α = 0.05 and with a power of
80% a study sample size of 96 patients is needed. Taking
into consideration the estimate of approximately 14
patients which will not complete the treatment, a total
number of 110 patients should be randomised.
The overall survival will be summarised by Kaplan-Meier
estimate and differences in therapy protocols will be ana-
lysed by univariate Cox-regression.
Various secondary endpoints will be evaluated in this
study as well. Disease free survival, measured from date of
operation, will be summarised by Kaplan-Meier estimate.
One year after inclusion of the first patient an interim
analysis will be carried out which could result in stopping
arm B. The planning of the study is based on a fix sample
approach and not on groups sequential. Because the alpha
level of the interim analysis is set to α = 0.001, the sample
size calculated from a group sequential approach will be
similar to the sample size of the fixed study approach.
The main evaluation will be performed two years after the
last patient's enrolment.
There will be explicit stopping rules in place to terminate
the trial early in the unlikely event that an unacceptably
high rate of treatment related deaths (TRD) is observed.
TRD will be monitored using the design of Thall and
Simon [16]. A non-informative Beta prior distribution
(i.e., B (0.015, 0.085) for TRD rate is assumed. The trial
will be stopped if at any point during the trial there is a
greater than 90% probability that the true TRD rate is
greater than 0.05. Each patient will subsequently be eval-
uated and, an independent safety board will be consulted
in making decision.
In view of the poor prognosis of the patient group, there
will be no explicit stopping rules based on the overall
number of toxicities, since even high rates of reversible
toxicities seem acceptable if there is a large survival gain.
Patients can withdraw from study participation at any
time. Patients are taken off the study if unacceptable tox-
icity appears. Unacceptable toxicity is defined as unex-
pected serious side effects or irreversible Grade 4 toxicity.
Patients who withdraw from the study may be treated
with 5-FU and folinic acid or with gemcitabine. The deci-
sion will be based on the individual reasons for withdraw-
ing from the study.
One year after inclusion of the first patient an interim
analysis will be done. If at this time point there already is
a significant difference between both groups favouring the
Virginia Mason scheme (p < 0.001) group B (5-FU/Folinic
acid) will be stopped and replaced by group C (chemora-
diation without interferon alpha).
Discussion
The role of adjuvant therapy in potentially curatively
resected adenocarcinoma of the pancreas remains a mat-
ter of debate. As the first, large multi-centre randomised
controlled trial (RCT), the ESPAC-1-Trial clearly favoured
adjuvant chemotherapy over postoperative chemoradia-
tion [3]. However the quality of the radio-chemothera-
peutic regimen in the ESPAC-1-Trial has been disputed.
The Virgina Mason study group in Seattle, USA, published
very promising data in phase-II-study involving immuno-
therapy and chemoradiation in the adjuvant setting [4].
The reliability of the data has been intensively discussed
and there even a source-data-verification was performed
by the National Cancer Institute (NCI). In the current set-
ting with a reference adjuvant treatment from an RCT and
very promising data from a phase-II-trial, there is the ideal
basis for a controlled trial comparing the two most current
and successful regimen. Being a centre focusing on pan-
creatic diseases and especially malignancies we therefore
planned and conduct such a trial.
The CapRI study is an open, randomised controlled trial
investigating the survival of patients after potentially cur-
ative resection of a pancreatic adenocarcinoma treated
adjuvant with 5-FU, cisplatin, INTRON A combined with
radiation or 5-FU plus folinic acid. The role and the mech-BMC Cancer 2005, 5:37 http://www.biomedcentral.com/1471-2407/5/37
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anism of interferon alpha 2b in patient's chemoradiation
regimen are evaluated. The toxicity, the disease-free
interval and the quality of life are assessed. Different fac-
tors are tested for a potential role as predictive marker.
The results of the CapRI trial will definitely advance clini-
cal and scientific knowledge on the adjuvant treatment of
pancreatic carcinoma as it may confirm or de-mystify the
remarkable results from the Virginia Mason study group.
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